Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2014
At a glance
- Drugs RPA 102 (Primary)
- Indications Anthrax
- Focus Pharmacodynamics
- Sponsors VaxGen
- 14 Mar 2014 updated to full profile and released.
- 05 Nov 2010 New trial record.